TrovaGene (NASDAQ:TROV) Given a $8.00 Price Target by Maxim Group Analysts

TrovaGene (NASDAQ:TROV) has been assigned a $8.00 price objective by investment analysts at Maxim Group in a research note issued to investors on Tuesday, April 2nd, TipRanks reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Maxim Group’s price objective points to a potential upside of 135.29% from the stock’s current price.

A number of other brokerages also recently commented on TROV. Zacks Investment Research upgraded shares of TrovaGene from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a report on Tuesday, March 12th. Noble Financial set a $20.00 target price on TrovaGene and gave the company an “outperform” rating in a research note on Friday, March 8th. Finally, ValuEngine upgraded TrovaGene from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $18.88.

Shares of TROV stock traded down $0.03 on Tuesday, hitting $3.40. The stock had a trading volume of 185,945 shares, compared to its average volume of 934,032. The company has a market capitalization of $16.88 million, a P/E ratio of -0.41 and a beta of 0.77. TrovaGene has a one year low of $2.52 and a one year high of $21.96.

TrovaGene (NASDAQ:TROV) last released its quarterly earnings data on Wednesday, March 6th. The medical research company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.05. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.08 million. TrovaGene had a negative return on equity of 142.49% and a negative net margin of 4,354.76%. On average, analysts predict that TrovaGene will post -4.02 EPS for the current year.

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its stake in TrovaGene by 192.7% in the 3rd quarter. Renaissance Technologies LLC now owns 596,606 shares of the medical research company’s stock worth $486,000 after purchasing an additional 392,804 shares during the period. Vanguard Group Inc boosted its position in shares of TrovaGene by 508.8% in the third quarter. Vanguard Group Inc now owns 239,029 shares of the medical research company’s stock worth $195,000 after buying an additional 199,767 shares during the period. Vanguard Group Inc. boosted its position in shares of TrovaGene by 508.8% in the third quarter. Vanguard Group Inc. now owns 239,029 shares of the medical research company’s stock worth $195,000 after buying an additional 199,767 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of TrovaGene in the third quarter worth about $265,000. 7.15% of the stock is owned by institutional investors and hedge funds.

TrovaGene Company Profile

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

Featured Story: Growth and Income Funds

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.